Prescrire Int. 2014 Oct;23(153):239.
Detailed case reports have confirmed that the dopamine agonist rotigotine, marketed in transdermal patches, exposes patients to the risk of impulse control disorders, even at the doses recommended for restless legs syndrome. In most cases, the symptoms regressed after reducing the dose or discontinuing the drug.
详细的病例报告证实，以透皮贴剂形式上市的多巴胺激动剂罗替戈汀会使患者面临冲动控制障碍的风险，即使是在用于治疗不宁腿综合征的推荐剂量下也是如此。在大多数情况下，减少剂量或停药后症状会消退。
